Article

Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model

Department of Psychiatry and Behavioral Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73151, USA.
Psychosomatics (Impact Factor: 1.67). 05/2005; 46(3):250-3. DOI: 10.1176/appi.psy.46.3.250
Source: PubMed

ABSTRACT Large numbers of Roux-en-Y gastric bypass (RYGB) surgery patients have psychiatric illnesses that are in part treated with medication preoperatively, but there are no objective data to guide psychiatric drug dosing postoperatively. An in vitro drug dissolution model was developed to approximate the gastrointestinal environment of the preoperative (control) and post-RYGB states. Medication tablets were placed in the two environments, and the median calculated weights of the dissolved portions were compared. Ten of 22 psychiatric medication preparations had significantly less dissolution and two had significantly greater dissolution in the post-RYGB environment, compared with the control environment. The results suggest a need for an in vivo study of serum drug levels after RYGB surgery in patients taking psychiatric medications. Differences in the pharmacokinetics of the postoperative RYGB patient may necessitate adjustments in dosing.

1 Follower
 · 
224 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The number of bariatric surgical procedures performed in the United States has increased steadily during the past decade. Currently accepted criteria for consideration of bariatric surgery include a body mass index (calculated as weight in kilograms divided by the square of height in meters) of 40 kg/m2 or greater (or >35 kg/m2 with obesity-related comorbidities), documented or high probability of failure of nonsurgical weight loss treatments, and assurance that the patient is well informed, motivated, and compliant. Appropriate patient selection is important in achieving optimal outcomes after bariatric surgery. In this article, we review our approach to the medical and psychological assessment of patients who want to undergo bariatric surgery. The medical evaluation is designed to identify and optimally treat medical comorbidities that may affect perioperative risks and long-term outcomes. The psychiatric and psychological assessment identifies factors that may influence long-term success in maintaining weight loss and prepares the patient for the lifestyle changes needed both before and after surgery.
    Mayo Clinic Proceedings 11/2006; 81(10 Suppl):S11-7. DOI:10.1016/S0025-6196(11)61176-2 · 5.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: More than half of gastric bypass patients take antidepressants preoperatively, presenting some unique considerations with this patient population. The challenges associated with antidepressant medications are experienced both preoperatively and postoperatively. As the gastric bypass option becomes more readily used in the treatment of obesity, the requirement for understanding the effect of this procedure on any alteration of medications will become more clinically important. The purpose of this paper is to present an overview of the potential challenges in providing optimal patient care for the gastric bypass patient who is taking antidepressant medications.
    Journal of PeriAnesthesia Nursing 04/2007; 22(2):108-21; quiz 122-4. DOI:10.1016/j.jopan.2006.11.005 · 0.89 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Promising data regarding the safety and efficacy of gastric bypass surgery (GBS) as an option to address obesity in the transplant population are emerging. The data lack on how GBS may alter the pharmacokinetics (PK) of modern immunosuppression. The objective of this study was to describe the alterations in the PK of modern immunosuppressants and the GBS population. Data are presented on six subjects who participated in this trial--four were on dialysis and two were renal transplant recipients. Dialysis-dependent bypass subjects received a single dose of 6 mg of sirolimus, two 4-mg doses of tacrolimus and two 1000-mg doses of mycophenolate mofetil (MMF) over the 24-h study period. Transplant recipients continued their current regimen. Maximum plasma concentration (C(max)), time to reach the maximum plasma concentration (T(max)) and the area under the plasma concentration vs. time curve (AUC(0-12) and AUC(0-infinity) where appropriate) were calculated for tacrolimus, sirolimus, mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG). Significant inter-patient variability in the C(max), T(max) and AUC of tacrolimus, sirolimus MPA and MPAG was observed. A notable difference in the AUC:dose ratio for tacrolimus was seen when comparing data with published data in the non-bypass population. Similar differences in PK were seen with sirolimus, MPA and MPAG. When comparing the PK of sirolimus, tacrolimus, MPA and MPAG to published PK data in the non-bypass population, significant differences are observed. It is likely that transplant recipients with GBS would need higher doses of tacrolimus, sirolimus and MMF to provide similar exposure to a non-bypass patient.
    Clinical Transplantation 05/2007; 22(3):281-91. DOI:10.1111/j.1399-0012.2007.00783.x · 1.49 Impact Factor
Show more

Preview

Download
17 Downloads
Available from